Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Provincial Landscape
Snapshot: 2026-09-04
Hong Kong Multiple Myeloma Active Trials & Centers
As of 2026-09-04, there are 1 active clinical trials for multiple myeloma hosted across 1 tertiary medical centers in Hong Kong (including Queen Mary Hospital).
Active Trials
1
Hospitals
1
Therapies
Oral Small-Molecule Agents
Participating Medical Centers (1)
Queen Mary Hospital
Active Studies in Hong Kong (1)
Population synthesized by CMDNShowing 1 published English records of 1 registry trials.
Phase IIICTR20232917
RecruitingA Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Population: Newly diagnosed/Maintenance
Target: Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
Study Sites: Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University、Jiangsu Province Hospital 等 37 家中心